BioSyent Secures Rights to Acquire Tibelia® Hormone Therapy Assets

BioSyent Inc. has acquired Tibelia®, a hormone replacement therapy drug, from Novalon SA and Mithra Pharmaceuticals SA, gaining global rights and IP for EUR 2.8 million. The acquisition includes IP, licensing, and distribution agreements, as well as inventory and equipment. BioSyent, which has marketed Tibella® in Canada since 2020, expects this deal to enhance its women's health product portfolio and boost its EBITDA by 12%.

Introduction:
BioSyent Inc. (TSX Venture: RX), a profitable growth-oriented specialty pharmaceutical company, recently announced the acquisition of Tibelia®, a hormone replacement therapy drug. This acquisition, which grants BioSyent global rights, intellectual property (IP), and distribution agreements, is expected to enhance the company's women's health product portfolio and boost its EBITDA by 12% [1].

Background:
Tibolone, the active ingredient in Tibelia®, has been available for over 30 years for the treatment of menopausal symptoms. Novalon SA, a company that licensed and supplied tibolone to partners in 20 countries, including Canada, generated approximately EUR 2.1 million in revenue from this product in 2023 [1]. BioSyent Pharma Inc., a wholly-owned subsidiary of BioSyent, has been marketing Tibelia® in Canada since 2020 under the brand name Tibella®.

Acquisition Details:
Under an Asset Purchase Agreement, BioSyent Pharma Inc. acquired Tibelia® assets, including IP, global rights, certain licensing, distribution, and supply agreements, inventory, and equipment, for a cash consideration of up to EUR 2.8 million [1]. This acquisition enables BioSyent to supply Tibelia® around the world, produce the product directly, and provide incremental earnings to its 2023 EBITDA.

Impact on BioSyent:
René Goehrum, President and CEO of BioSyent, commented, "Tibella® has been an important part of our women's health product portfolio since we first launched it in Canada in 2020. This acquisition enables BioSyent to supply this trusted product around the world to both new and existing markets and to produce the product directly, providing incremental earnings of approximately 12% to our 2023 EBITDA" [1]. This strategic acquisition aligns with BioSyent's strategic priorities of long-term growth and portfolio diversification.

Conclusion:
BioSyent's acquisition of Tibelia® is a significant strategic move that enhances the company's women's health product portfolio and boosts its EBITDA. By acquiring the global rights, IP, and distribution agreements for Tibolone, BioSyent positions itself to expand its reach and provide a trusted product to both new and existing markets.

References:
[1] GlobeNewswire. BioSyent Announces Agreement to Purchase Tibelia® tibolone Assets. https://www.globenewswire.com/news-release/2024/09/20/2949694/0/en/BioSyent-Announces-Agreement-to-Purchase-Tibelia-tibolone-Assets.html